Zweig-DiMenna Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Planet Labs
PL
|
+$24.4M |
| 2 |
Revolution Medicines
RVMD
|
+$16.3M |
| 3 |
Analog Devices
ADI
|
+$14.3M |
| 4 |
Capital One
COF
|
+$14.3M |
| 5 |
Advanced Micro Devices
AMD
|
+$11.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$33.4M |
| 2 |
CrowdStrike
CRWD
|
+$14.8M |
| 3 |
Coherent
COHR
|
+$8.62M |
| 4 |
HUT
Hut 8
HUT
|
+$8.23M |
| 5 |
GeneDx Holdings
WGS
|
+$6.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.53% |
| 2 | Industrials | 11.92% |
| 3 | Healthcare | 9.05% |
| 4 | Financials | 7.88% |
| 5 | Communication Services | 7.69% |
No holdings matched the selected filter criteria.
Similar funds
Zweig-DiMenna Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Zweig-DiMenna Associates held 82 positions worth $1.1B, up 53% from $722M the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Zweig-DiMenna Associates deployed $41M of net new capital in Q2 2026, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Planet Labs: 660,200 shares worth $21.9M.
By sector, the portfolio is most concentrated in Technology at 55% of assets, up from 44% a quarter earlier, followed by Industrials and Healthcare.
On the sell side, the largest reduction was Amazon, an estimated $33.4M trimmed.
- Zweig-DiMenna Associates's largest Q2 2026 buy was Planet Labs: 660,200 shares worth $21.9M.
- Zweig-DiMenna Associates added most to Revolution Medicines in Q2 2026, an estimated $16.3M increase.
- Zweig-DiMenna Associates's biggest Q2 2026 reduction was Amazon, cutting an estimated $33.4M.
- Zweig-DiMenna Associates fully exited Synopsys in Q2 2026, selling an estimated $5.74M.
- Zweig-DiMenna Associates's ten largest holdings make up 39% of its $1.1B portfolio in Q2 2026.
- Zweig-DiMenna Associates opened 21 new positions and closed 12 in Q2 2026.
- Zweig-DiMenna Associates's portfolio value rose 53% quarter-over-quarter to $1.1B.
Based on Zweig-DiMenna Associates's 13F filing for Q2 2026, filed 13 Aug 2026.